Compare DWSN & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DWSN | VRCA |
|---|---|---|
| Founded | 1952 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 117.5M |
| IPO Year | 1995 | 2018 |
| Metric | DWSN | VRCA |
|---|---|---|
| Price | $5.79 | $6.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 90.3K | 38.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $145,773,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | $23.96 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.27 | $0.70 |
| 52 Week High | $6.25 | $9.82 |
| Indicator | DWSN | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 68.22 | 49.65 |
| Support Level | $1.75 | $5.32 |
| Resistance Level | N/A | $6.48 |
| Average True Range (ATR) | 0.43 | 0.49 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 80.19 | 44.71 |
Dawson Geophysical Co provides seismic data acquisition services mainly to providers of multi-client data libraries and directly to onshore oil and natural gas exploration and development companies in the continental U.S. and Canada. The demand for seismic services is largely influenced by drilling and completion activity, exploration budgets, and prevailing and anticipated crude oil and natural gas prices. Its data acquisition crews serve companies engaged in the exploration and development of oil and gas on land and in land-to-water transition areas. The business operates through two reportable segments, with U.S. operations generating the majority of revenue and Canada operations contributing additionally.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.